Pilot Study of a Novel Short-Cycle Antiretroviral Treatment Interruption Strategy: 48-Week Results of the Five-Days-On, Two-Days-Off (FOTO) Study
- 1 February 2007
- journal article
- clinical trial
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 8 (1) , 19-23
- https://doi.org/10.1310/hct0801-19
Abstract
Purpose: The challenges associated with daily lifelong antiretroviral therapy (ART) have stimulated interest in alternative treatment schedules, including planned, cyclical interruptions of therapy in patients with virologic suppression and sufficient CD4+ T-cell counts. Method: We conducted a 48-week, open-label, single-arm, prospective pilot study of a novel short-cycle treatment interruption strategy. Upon enrollment, 30 HIV+ individuals with a history of durable viral suppression on daily ART changed their weekly treatment schedule to 5 consecutive days on treatment (typically Monday through Friday) followed by 2 days off treatment (five-on, two-off, or FOTO treatment schedule). Results: At 24 and 48 weeks, as-treated analysis revealed that virologic suppression was maintained in 26/29 subjects (89.6%), including 100% of subjects taking efavirenz-based regimens. Participants adhered well to the FOTO treatment schedule and expressed a strong preference for the FOTO treatment schedule compared to daily ART. Conclusion: If validated, the FOTO treatment strategy with efavirenz-based regimens could avoid the viremia witnessed in longer cycle structured treatment interruptions yet still ameliorate a number of problems associated with the current paradigm of daily ART for HIV infection, including the high cost of therapy and the pill fatigue that, in many patients, leads to erratic adherence and ultimately treatment failure.Keywords
This publication has 10 references indexed in Scilit:
- CD4+ Count–Guided Interruption of Antiretroviral TreatmentNew England Journal of Medicine, 2006
- Less Than 95% Adherence to Nonnucleoside Reverse‐Transcriptase Inhibitor Therapy Can Lead to Viral SuppressionClinical Infectious Diseases, 2006
- Quality Assurance Program for Pharmacokinetic Assay of Antiretrovirals: ACTG Proficiency Testing for Pediatric and Adult Pharmacology Support Laboratories, 2003 to 2004Therapeutic Drug Monitoring, 2006
- Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected AdultsNew England Journal of Medicine, 2005
- Quality Assurance Program for Clinical Measurement of Antiretrovirals: AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology LaboratoriesAntimicrobial Agents and Chemotherapy, 2004
- Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trialAIDS, 2003
- Long‐Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic ParametersThe Journal of Infectious Diseases, 2003
- Reverse Phase High-Performance Liquid Chromatography Method for the Analysis of Amprenavir, Efavirenz, Indinavir, Lopinavir, Nelfinavir and Its Active Metabolite (M8), Ritonavir, and Saquinavir in Heparinized Human PlasmaTherapeutic Drug Monitoring, 2003
- Position Paper on Therapeutic Drug Monitoring of Antiretroviral AgentsAIDS Research and Human Retroviruses, 2002
- Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV InfectionAnnals of Internal Medicine, 2000